Employees: NN (None)Legal category: 5470Size: PMECreation date: 2017-12-18 (8 years)Status: ActiveBusiness sector: Activités des sociétés holdingLocation: DIVES-SUR-MER (14160), Calvados
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SPFPL PHARMAVENIR 2 : revenue, balance sheet and financial ratios
SPFPL PHARMAVENIR 2 is a French company
founded 8 years ago,
specialized in the sector Activités des sociétés holding.
Based in DIVES-SUR-MER (14160),
this company of category PME
shows in 2024 a revenue of 1€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SPFPL PHARMAVENIR 2 (SIREN 833572118)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
1 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
86 332 €
85 371 €
81 989 €
85 156 €
185 046 €
-17 490 €
75 213 €
77 556 €
EBITDA
-1 377 €
-1 327 €
-1 310 €
-1 306 €
-1 532 €
-701 €
-1 623 €
-3 919 €
Net margin
N/C
8537100.0%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
Im Jahr 2025 erzielt SPFPL PHARMAVENIR 2 ein positives Nettoergebnis von 86 k€. Entwicklung 2018-2025: 78 k€ -> 86 k€.
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
-1 377 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
-1 377 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
86 332 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
Die Verschuldungsquote (= Finanzschulden / Eigenkapital x 100) beträgt 37%. Die Verschuldung bleibt unter Kontrolle. Die finanzielle Autonomie (= Eigenkapital / Bilanzsumme x 100) erreicht 25%. Das Gleichgewicht zwischen Eigenkapital und Schulden ist zufriedenstellend. Die Schuldenrückzahlungskapazität zeigt, dass es 4.1 Jahre Cashflow braucht. Diese Kennzahl bleibt innerhalb der üblichen Bankstandards.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
36.696%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
25.056%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
4.053
Solvency indicators evolution SPFPL PHARMAVENIR 2
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
281.316
212.289
222.739
124.509
99.361
76.974
50.139
36.696
Financial autonomy
73.727
67.892
68.933
55.4
49.775
43.451
31.26
25.056
Repayment capacity
11.909
11.229
-43.714
3.694
7.236
6.327
5.094
4.053
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
8537200.0%
None%
Sector positioning
Verschuldungsgrad
36.72025
2023
2024
2025
Q1: 0.04
Med: 8.09
Q3: 54.01
Average-9 pts over 3 years
Im Jahr 2025 liegt über dem Median der Branche das verschuldungsgrad von SPFPL PHARMAVENIR 2 (36.70). Dieses Verhältnis misst das Gewicht der Schulden im Verhältnis zum Eigenkapital. Eine Reduzierung könnte die finanzielle Stärke verbessern.
Finanzielle Autonomie
25.06%2025
2023
2024
2025
Q1: 21.27%
Med: 67.32%
Q3: 92.99%
Average-13 pts over 3 years
Im Jahr 2025 liegt unter dem Median der Branche das finanzielle autonomie von SPFPL PHARMAVENIR 2 (25.1%). Dieses Verhältnis stellt den Anteil des Eigenkapitals an der Gesamtfinanzierung dar. Eine Verbesserung würde die Wettbewerbsposition stärken.
Rückzahlungsfähigkeit
4.05 ans2025
2023
2024
2025
Q1: 0.0 ans
Med: 0.19 ans
Q3: 2.98 ans
Average
Im Jahr 2025 liegt über dem Median der Branche das rückzahlungsfähigkeit von SPFPL PHARMAVENIR 2 (4.0 ans). Dieses Verhältnis gibt die Anzahl der Jahre an, die zur Rückzahlung der Schulden mit dem Cashflow benötigt werden. Eine Reduzierung könnte die finanzielle Stärke verbessern.
Liquidity ratios
Die Liquiditätsquote beträgt 14.19. Das Unternehmen verfügt über 2€ liquide Mittel für jeden 1€ kurzfristiger Schulden.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
14.192
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
8.217
4.532
1.334
3.587
38.638
18.854
16.113
14.192
Interest coverage
-331.666
-966.235
-1982.739
-842.037
-904.364
-1181.985
-1092.012
-1007.48
Sector positioning
Liquiditätsquote
14.192025
2023
2024
2025
Q1: 161.8
Med: 834.57
Q3: 4761.54
Average
Im Jahr 2025 liegt unter dem Median der Branche das liquiditätsquote von SPFPL PHARMAVENIR 2 (14.19). Dieses Verhältnis misst die Fähigkeit, kurzfristige Schulden mit Umlaufvermögen zu decken. Eine Verbesserung würde die Wettbewerbsposition stärken.
Zinsdeckung
-1007.48x2025
2023
2024
2025
Q1: -62.1x
Med: 0.0x
Q3: 0.0x
Average
Im Jahr 2025 liegt unter dem Median der Branche das zinsdeckung von SPFPL PHARMAVENIR 2 (-1007.5x). Dieses Verhältnis gibt an, wie oft das Betriebsergebnis die Zinsaufwendungen deckt. Eine Verbesserung würde die Wettbewerbsposition stärken.
Working capital requirement (WCR) and payment terms
Der Betriebskapitalbedarf (WCR) misst die zeitliche Lücke. Durchschnittliche Kundenzahlungsfrist: 0 Tage. Lieferantenfrist: 214 Tage. Ausgezeichnete Situation: Lieferanten finanzieren 214 Tage des Betriebszyklus.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
214 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SPFPL PHARMAVENIR 2
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
-87 437 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
0
0
Customer payment term (days)
0
0
0
0
0
0
0
0
Supplier payment term (days)
69
322
695
282
420
314
217
214
Positioning of SPFPL PHARMAVENIR 2 in its sector
Comparison with sector Activités des sociétés holding
Valuation estimate
Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions).
This range of 34 427€ to 1 060 957€ is provided for information purposes only and requires in-depth analysis to be confirmed.
Estimated enterprise value2025
Indicative
34k€177k€1060k€
177 311 €Range: 34 427€ - 1 060 957€
NAF 5 année 2025
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Activités des sociétés holding)
Compare SPFPL PHARMAVENIR 2 with other companies in the same sector:
Frequently asked questions about SPFPL PHARMAVENIR 2
What is the revenue of SPFPL PHARMAVENIR 2 ?
The revenue of SPFPL PHARMAVENIR 2 in 2024 is 1€.
Is SPFPL PHARMAVENIR 2 profitable?
Yes, SPFPL PHARMAVENIR 2 generated a net profit of 86 k€ in 2025.
Where is the headquarters of SPFPL PHARMAVENIR 2 ?
The headquarters of SPFPL PHARMAVENIR 2 is located in DIVES-SUR-MER (14160), in the department Calvados.
Where to find the tax return of SPFPL PHARMAVENIR 2 ?
The tax return of SPFPL PHARMAVENIR 2 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SPFPL PHARMAVENIR 2 operate?
SPFPL PHARMAVENIR 2 operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart